User profiles for Christine Mona
 | Christine MonaMolecular and Medical Pharmacology, UCLA Verified email at mednet.ucla.edu Cited by 658 |
Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective …
Fibroblast activation protein (FAP)–expressing cancer-associated fibroblasts confer
treatment resistance and promote metastasis and immunosuppression. Because FAP is …
treatment resistance and promote metastasis and immunosuppression. Because FAP is …
Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients
…, T Lindner, S Vauclin, C Mona… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Targeting cancer-associated fibroblasts (CAFs) has become an attractive goal for diagnostic
imaging and therapy because they can constitute as much as 90% of a tumor mass. The …
imaging and therapy because they can constitute as much as 90% of a tumor mass. The …
Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity
Purpose: Prostate-specific membrane antigen (PSMA) targeting radioligands deliver
radiation to PSMA-expressing cells. However, the relationship between PSMA levels and …
radiation to PSMA-expressing cells. However, the relationship between PSMA levels and …
Immune-checkpoint blockade enhances 225Ac-PSMA617 efficacy in a mouse model of prostate cancer
J Czernin, K Current, CE Mona… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–targeted radionuclide therapy (RNT) may
increase tumor immunogenicity. We aimed at exploiting this effect by combining RNT with …
increase tumor immunogenicity. We aimed at exploiting this effect by combining RNT with …
[HTML][HTML] Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
…, S Evans-Axelsson, AD Stuparu, R Slavik, CE Mona… - EJNMMI research, 2018 - Springer
Background Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT)
is a promising yet not curative approach in castration-resistant (CR) prostate cancer (PC). …
is a promising yet not curative approach in castration-resistant (CR) prostate cancer (PC). …
Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy (RLT) is effective
against prostate cancer (PCa), but all patients relapse eventually. Poor understanding of the …
against prostate cancer (PCa), but all patients relapse eventually. Poor understanding of the …
68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation
…, S Memarzadeh, MM Quinn, CE Mona… - European Journal of …, 2021 - Springer
A 36-year-old female patient diagnosed with invasive squamous cell carcinoma of the cervix
underwent an 18F-fluorodeoxyglucose ([18F] FDG) PET/CT scan (Figs. 1a and 2a: MIP, Fig. …
underwent an 18F-fluorodeoxyglucose ([18F] FDG) PET/CT scan (Figs. 1a and 2a: MIP, Fig. …
Detection threshold and reproducibility of 68Ga-PSMA11 PET/CT in a mouse model of prostate cancer
To improve prostate-specific membrane antigen (PSMA)–targeted theranostic approaches,
robust murine models of prostate cancer are needed. However, important characteristics of …
robust murine models of prostate cancer are needed. However, important characteristics of …
Design, synthesis, and biological evaluation of CXCR4 ligands
CE Mona, É Besserer-Offroy, J Cabana… - Organic & …, 2016 - pubs.rsc.org
A combination of the CXCR4 inverse agonist T140 with N-terminal CXCL12 oligopeptides
has produced the first nanomolar synthetic CXCR4 agonists. In these agonists, the inverse …
has produced the first nanomolar synthetic CXCR4 agonists. In these agonists, the inverse …